TRANS GENIC GROUP INC. Logo

TRANS GENIC GROUP INC.

Offers drug discovery CRO services (gene editing, trials) and business investment/consulting.

2342 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
福岡市中央区天神二丁目3番36号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Trans-Genic Group Inc. operates a hybrid business model centered on two core segments: Drug Discovery Support and Investment & Consulting. Its foundational Drug Discovery Support business provides comprehensive, seamless contract research organization (CRO) services for all stages of pharmaceutical development. Key offerings include the custom creation of genetically modified animals using genome editing technologies like CRISPR/Cas9, antibody production, and support for preclinical and clinical trials. This division assists clients from basic exploratory research to advanced drug development. The Investment & Consulting division focuses on promoting new ventures through M&A, and provides advisory, support, and investment services for business succession and corporate revitalization across various industries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-01 09:45
Registration Form
訂正確認書
Japanese 8.2 KB
2025-08-01 09:44
Annual Report
訂正有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 667.3 KB
2025-07-02 05:53
Regulatory News Service
訂正臨時報告書
Japanese 24.4 KB
2025-07-01 10:02
Post-Annual General Meeting Information
臨時報告書
Japanese 24.4 KB
2025-06-30 09:38
Registration Form
確認書
Japanese 8.6 KB
2025-06-30 09:37
Governance Information
内部統制報告書-第27期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-06-30 09:34
Annual Report
有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2025-06-13 10:13
Regulatory News Service
臨時報告書
Japanese 21.2 KB
2025-04-23 09:55
Regulatory News Service
臨時報告書
Japanese 20.1 KB
2024-11-13 02:42
Report Publication Announcement
確認書
Japanese 8.5 KB
2024-11-13 02:41
Interim Report
半期報告書-第27期(2024/04/01-2025/03/31)
Japanese 191.9 KB
2024-06-24 08:30
M&A Activity
臨時報告書
Japanese 19.8 KB
2024-06-21 07:03
Annual Report
有価証券報告書-第26期(2023/04/01-2024/03/31)
Japanese 1.0 MB
2024-06-21 06:31
Regulatory News Service
確認書
Japanese 8.1 KB
2024-06-21 06:28
Regulatory News Service
内部統制報告書-第26期(2023/04/01-2024/03/31)
Japanese 22.3 KB

Automate Your Workflow. Get a real-time feed of all TRANS GENIC GROUP INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for TRANS GENIC GROUP INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Biotech R&D using a miniature pig model, offering CRO services and biomaterials to pharma.
South Korea 149300
Arterra Bioscience Logo
Develops natural active ingredients via biotechnology for cosmetic, pharma, and food sectors.
Italy ABS
ASUA Inc. Logo
Consulting and solutions provider enhancing logistics safety and efficiency with IoT and telecom.
Japan 246A
Licenses patented material IP (MST®) to create higher-performance, lower-power semiconductors.
United States of America ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan 6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia N/A
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan 6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.